Cormorant Asset Management, LP - May 6, 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
10%+ Owner
Signature
/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner
Stock symbol
EYPT
Transactions as of
May 6, 2024
Transactions value $
$10,081,721
Form type
4
Date filed
5/8/2024, 04:23 PM
Previous filing
Apr 22, 2024
Next filing
Sep 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Purchase $7.52M +643K +8.6% $11.70 8.12M May 6, 2024 See Footnote F1, F2
transaction EYPT Common Stock Purchase $2.56M +207K +2.55% $12.36 8.33M May 6, 2024 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F2 Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $11.08 to $12.07 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.
F3 Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.08 to $12.95 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.